FDA Approves Treatment for Adults with Secondary Hyperparathyroidism on Hemodialysis
February 8th 2017The FDA has greenlighted Amgen’s Parsabiv (etelcalcetide) as the first therapy in 12 years approved to treat secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis.
Read More